Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets

Table 1 2008 Prices for most-commonly used first-line ARV regimens

	Median (25^th, 75^th percentile) Regimen Prices* in USD
	Low Income	Lower-Middle Income	Upper-Middle Income
Old First-Line Regimens from 2003 WHO Guidelines:
3TC/NVP/d4T30	88 (83, 90)	87 (80, 151)	110 (84, 222)
EFV+3TC/d4T30	198 (183, 223)	147 (52, 253)	211 (172, 235)
3TC/NVP/ZDV**	154 (144, 162)	172 (154, 259)	161 (161, 189)
EFV+3TC/ZDV**	260 (246, 286)	216 (118, 298)	326 (260, 370)
New First-Line Regimens from 2006, 2009 WHO Guidelines:
3TC+NVP+TDF**	244 (226, 278)	256 (244, 288)	387 (311, 591)
EFV+3TC+TDF**	349 (321, 399)	301 (207, 392)	477 (404, 527)
FTC/TDF+NVP**	361 (325, 366)	399 (292, 427)	525 (368, 726)
EFV+FTC/TDF**	465 (419, 487)	443 (256, 531)	616 (461, 663)
ABC+3TC+NVP	398 (361, 450)	418 (392, 457)	491 (443, 705)
ABC+EFV+3TC	503 (455, 571)	463 (355, 561)	581 (536, 641)
ABC+FTC+NVP	n/a^§	n/a^§	n/a^§
ABC+EFV+FTC	n/a^§	n/a^§	n/a^§

*price/person/year calculated using the least expensive ARVs to create each regimen (see methods section)
**first-line regimens recommended in 2009 WHO guidelines
^§price data unavailable; less than 5 purchases for at least one ARV in regimen